Table 3.
Characteristics of Lung NET Patients Treated with EVE Included in the Eligible Studies
| Study | Lung NET Treated with EVE (n) | EVE Single Agent or Combo | TC (%) | AC (%) | NOS (%) | Criteria Inclusion | Criteria Stratification | Median Age (Range) | Male (%) | Caucasian (%) | PS=0 (%) | Liver mts (%) | Prior SSA (%) | Prior cht (%) | Prior RT (%) | Functioning Disease (%) | Elevated CgA at Entry |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lung subgroup analysis RADIANT-2 | 33 | + OCT LAR | 76 | 18 | 6 | -Carcinoid syndrome -Any line -Baseline PD |
NR | 60 (22–83) (general population) | 60.6 | NR | 45.5 | 92 (general population) | 67 | 39 | NR | 100 | 1279 (median value) |
| Lung subgroup analysis RADIANT-4 | 63 | Single agent | 35 | 7 | 58 | - Grade 1–2 (KI67 <20%) [WHO 2010] -No syndrome -Any line -Baseline PD |
Previous SSA, tumor origin, PS | 67 (34–86) | 51 | 84 | 73 | 68.3 | 43 | 39 | 40 | 0 | 46% (general population) |
| ITMO | 11 | + OCT LAR | NR | NR | NR | -TC and AC [WHO 2004] - First line |
NR | 58 (25–76) (general population) |
58 (general population) |
100 | 100 | NR | 0 | 0 | 0 | 26 (general population) |
76% (general population) |
| LUNA | 83 (of whom 78 lung NET) | 42 single agent | 29 | 71 | 0 | - TC and AC [WHO 2004] -Any line -Baseline PD -No severe syndrome |
TC vs AC and first line vs others | 66 (61–73) | 55 | 100 | 57 | 81 | 45 | 40.5 | 26 | 17 | NR |
| 41 PAS LAR | 32 | 68 | 0 | 61 (56–69) | 68 | 98 | 66 | 76 | 46 | 58.5 | 19.5 | 22 | NR |
Abbreviations: PD, progressive disease; TC, typical carcinoid; AC, atypical carcinoid; NOS, not otherwise specified; PS, performance status; SSA, somatostatin analogue; CgA, plasma chromogranin A; EVE, everolimus; NR, not reported; RT, radiotherapy (can include peptide receptor radionuclide therapy); PAS, pasireotide; OCT, octreotide.